Kapitalo Investimentos Ltda Takes Position in HealthEquity, Inc. (NASDAQ:HQY)

Kapitalo Investimentos Ltda purchased a new position in HealthEquity, Inc. (NASDAQ:HQY) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 933 shares of the company’s stock, valued at approximately $90,000.

Other hedge funds have also recently bought and sold shares of the company. Northern Trust Corp lifted its holdings in shares of HealthEquity by 11.7% in the fourth quarter. Northern Trust Corp now owns 1,155,043 shares of the company’s stock valued at $110,826,000 after purchasing an additional 121,001 shares in the last quarter. Oberweis Asset Management Inc. lifted its stake in HealthEquity by 8.4% in the 4th quarter. Oberweis Asset Management Inc. now owns 91,500 shares of the company’s stock valued at $8,779,000 after buying an additional 7,100 shares in the last quarter. Hancock Whitney Corp lifted its stake in HealthEquity by 1.0% in the 4th quarter. Hancock Whitney Corp now owns 13,326 shares of the company’s stock valued at $1,279,000 after buying an additional 133 shares in the last quarter. Voya Investment Management LLC increased its position in HealthEquity by 70.2% during the fourth quarter. Voya Investment Management LLC now owns 78,072 shares of the company’s stock worth $7,491,000 after buying an additional 32,204 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of HealthEquity in the fourth quarter worth $768,000. 99.55% of the stock is owned by hedge funds and other institutional investors.

HealthEquity Price Performance

HQY stock opened at $85.72 on Thursday. The firm has a market cap of $7.41 billion, a P/E ratio of 78.64, a price-to-earnings-growth ratio of 1.60 and a beta of 0.49. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. HealthEquity, Inc. has a 1 year low of $65.01 and a 1 year high of $115.59. The stock has a 50-day simple moving average of $90.32 and a 200-day simple moving average of $96.43.

Insider Activity at HealthEquity

In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $111.29, for a total transaction of $639,917.50. Following the transaction, the director now owns 78,219 shares of the company’s stock, valued at approximately $8,704,992.51. This trade represents a 6.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Henry Fiore sold 8,881 shares of the business’s stock in a transaction on Friday, April 4th. The stock was sold at an average price of $78.26, for a total value of $695,027.06. Following the completion of the sale, the executive vice president now directly owns 56,655 shares in the company, valued at $4,433,820.30. This represents a 13.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,381 shares of company stock valued at $1,781,432 over the last three months. 2.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on HQY shares. Wells Fargo & Company boosted their target price on shares of HealthEquity from $110.00 to $125.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. The Goldman Sachs Group decreased their target price on shares of HealthEquity from $107.00 to $94.00 and set a “neutral” rating on the stock in a research report on Thursday, March 27th. Barrington Research reiterated an “outperform” rating and issued a $112.00 price target on shares of HealthEquity in a report on Friday, April 11th. Raymond James raised HealthEquity from an “outperform” rating to a “strong-buy” rating and lowered their price objective for the company from $120.00 to $115.00 in a research report on Tuesday, March 25th. Finally, KeyCorp dropped their target price on HealthEquity from $110.00 to $100.00 and set an “overweight” rating for the company in a research note on Wednesday, April 16th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $111.75.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.